2021-10-28 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥1,024,320,530.52, representing a year-on-year increase of 62,199.88%[2]. - The net profit attributable to shareholders for the same period was ¥396,762,938.64, with a year-to-date net profit of ¥1,333,895,747.93, indicating a significant turnaround[2][4]. - Total revenue for the first three quarters of 2021 reached ¥3,085,775,466.38, a significant increase from ¥5,673,787.90 in the same period of 2020[14]. - Operating profit for the third quarter was ¥1,295,250,887.58, compared to a loss of ¥176,696,651.33 in the previous year[15]. - Net profit for the third quarter amounted to ¥1,333,895,747.93, a substantial recovery from a net loss of ¥175,891,311.14 in the same quarter of 2020[15]. - Basic earnings per share for the third quarter were ¥5.39, a recovery from a loss of ¥0.78 per share in the same quarter of 2020[16]. - The company reported a tax expense of ¥43,506,032.42 for the third quarter, reflecting its profitability[15]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥10,885,218,247.28, reflecting a 61.31% increase from the previous year[4][6]. - Total assets as of the end of the third quarter were ¥10,885,218,247.28, compared to ¥6,748,073,711.72 at the same time last year[12]. - Total liabilities increased to ¥3,465,059,903.72 from ¥677,219,551.36 year-over-year, reflecting growth in financial obligations[12]. - The company's equity attributable to shareholders reached ¥7,420,158,343.56, up from ¥6,070,854,160.36 in the previous year[13]. Cash Flow - The company reported a net cash flow from operating activities of ¥474,750,433.68 for the quarter, compared to a net outflow in the same period last year[4][6]. - The net cash flow from operating activities for the first three quarters of 2021 was approximately ¥1.24 billion, a significant improvement from a net outflow of approximately ¥171.97 million in the same period of 2020[17]. - Cash inflow from investment activities totaled approximately ¥3.97 billion, compared to ¥2.58 billion in the previous year[18]. - The net cash flow from investment activities was a negative ¥2.23 billion, an improvement from a negative ¥3.28 billion in the same period of 2020[18]. - Cash inflow from financing activities was approximately ¥1.58 billion, down from approximately ¥4.98 billion in the previous year[18]. - The net increase in cash and cash equivalents for the period was approximately ¥418.77 million, compared to an increase of approximately ¥1.48 billion in the same period of 2020[18]. - The total cash and cash equivalents at the end of the period stood at approximately ¥4.86 billion, up from approximately ¥1.68 billion at the end of the same period last year[18]. Research and Development - Research and development expenses totaled ¥108,690,828.22, accounting for 10.61% of operating revenue, a decrease of 4166.97 basis points compared to the previous year[4][6]. - Research and development expenses for the third quarter totaled ¥655,770,308.43, up from ¥176,716,264.71 in the previous year, indicating a focus on innovation[15]. - The company plans to continue increasing R&D investment to maintain its technological and quality advantages in future products[6]. - The company plans to enhance its synthetic biology vaccine technology platform and accelerate the R&D and industrialization of innovative vaccines[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,018[6]. - The total number of shares held by the top 10 unrestricted shareholders was 98,067,097, with HKSCC NOMINEES LIMITED holding the largest share at 39.63%[8]. Inventory and Current Assets - As of September 30, 2021, the company's total current assets reached ¥8,569,985,663.65, an increase from ¥5,420,643,756.35 in the previous year, representing a growth of approximately 58.5%[10]. - The cash and cash equivalents amounted to ¥5,139,096,202.52, up from ¥4,447,029,798.94, indicating a year-over-year increase of about 15.6%[10]. - The company's inventory increased significantly to ¥590,097,330.71 from ¥170,512,571.77, reflecting a growth of approximately 246.5%[11]. - The total non-current assets as of September 30, 2021, were ¥2,315,232,583.63, compared to ¥1,327,429,955.37 in the previous year, marking an increase of about 74.6%[11]. - The company's trading financial assets increased to ¥1,985,695,589.05 from ¥666,639,616.43, showing a growth of approximately 197.5%[11]. - Accounts receivable rose to ¥481,556,188.09 from ¥22,143,420.00, representing a significant increase of about 2065.5%[11]. New Developments - The company established a new subsidiary, 康希诺（上海）生物科技有限公司, to accelerate the development of an innovative vaccine research and production base in Shanghai[9]. - The self-developed A group C group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) received its first batch release certificate, indicating its official market launch in China[9]. - The company recognized non-recurring gains of ¥21,327,598.48 in the quarter, primarily from government subsidies and fair value changes of financial assets[5].